{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:54:56Z","timestamp":1781758496648,"version":"3.54.5"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human epidermal growth factor receptor 2 (HER2) expression in breast cancer (BC) determines the options for targeted therapy. Multiparametric MRI (mpMRI) has the potential for noninvasive HER2 status prediction but remains underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To develop and validate an mpMRI-based nomogram incorporating clinicopathological factors for predicting HER2 status in BC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this retrospective analysis, 313 BC patients were classified as HER2-overexpression, HER2-low, or HER2-zero on the basis of immunohistochemistry and fluorescence\n                      <jats:italic>in situ<\/jats:italic>\n                      hybridization. The patients were divided into training (n=232) and validation (n=81) datasets. Clinicopathological factors and mpMRI parameters were analyzed. Logistic regression identified independent predictors that were used to construct and validate the nomogram. Discrimination was evaluated by the area under the receiver operating characteristic curve (AUC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CA125, Ki-67, the minimum apparent diffusion coefficient (ADC-min), and early-phase maximum enhancement (ME) differed significantly among the HER2 subgroups. The nomogram integrating these factors achieved AUCs of 0.762 (95% CI: 0.686\u20130.838) and 0.738 (95% CI: 0.594\u20130.882) in differentiating HER2-over\/HER2-low from HER2-zero in the training and validation datasets, respectively. Differentiation between the HER2-over and HER2-low subtypes exhibited AUCs of 0.719 and 0.772, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our nomogram, which combines mpMRI and clinicopathological variables, effectively predicts HER2 expression in BC patients, providing a promising noninvasive clinical tool to guide targeted therapy selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1824808","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:38:34Z","timestamp":1781757514000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Yi","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Radiology, Meizhou People\u2019s Hospital","place":["Meizhou, China"]},{"name":"Department of Radiology, Affiliated Meizhou Hospital of Shantou University Medical College","place":["Meizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, Meizhou People\u2019s Hospital","place":["Meizhou, China"]},{"name":"Department of Radiology, Affiliated Meizhou Hospital of Shantou University Medical College","place":["Meizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Radiology, Meizhou People\u2019s Hospital","place":["Meizhou, China"]},{"name":"Department of Radiology, Affiliated Meizhou Hospital of Shantou University Medical College","place":["Meizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Radiology, Affiliated Meizhou Hospital of Shantou University Medical College","place":["Meizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Affiliated Meizhou Hospital of Shantou University Medical College","place":["Meizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, Affiliated Meizhou Hospital of Shantou University Medical College","place":["Meizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangguang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, Affiliated Meizhou Hospital of Shantou University Medical College","place":["Meizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuozhi","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shantou Central Hospital","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Meizhou People\u2019s Hospital","place":["Meizhou, China"]},{"name":"Department of Radiology, Affiliated Meizhou Hospital of Shantou University Medical College","place":["Meizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00730-2","article-title":"Global, regional, and national burden of breast cancer among females, 1990\u20132023, with forecasts to 2050: a systematic analysis for the global burden of disease study 2023","volume":"27","author":"Bhangdia","year":"2026","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101615","article-title":"Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer","volume":"8","author":"Viale","year":"2023","journal-title":"ESMO Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2019182947","article-title":"Breast MRI: state of the art","volume":"292","author":"Mann","year":"2019","journal-title":"Radiology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010126","article-title":"Current biological, pathological and clinical landscape of HER2-low breast cancer","volume":"15","author":"Zhang","year":"2022","journal-title":"Cancers"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab deruxtecan in breast cancer","volume":"198","author":"Mart\u00edn","year":"2024","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188849","article-title":"Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low","volume":"1878","author":"Fan","year":"2023","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013college of American pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/cancers13112824","article-title":"HER2-low breast cancer: molecular characteristics and prognosis","volume":"13","author":"Agostinetto","year":"2021"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2020.05.040","article-title":"Radiomics signatures based on multiparametric MRI for the preoperative prediction of the HER2 status of patients with breast cancer","volume":"28","author":"Zhou","year":"2021","journal-title":"Acad Radiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.08.1229","article-title":"Is breast MRI helpful in the evaluation of inconclusive mammographic findings","volume":"193","author":"Moy","year":"2009","journal-title":"Am J Roentgenol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.25790","article-title":"Multiparametric MRI of the breast: A review","volume":"47","author":"Marino","year":"2018","journal-title":"J Magn Reson Imaging"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29875","article-title":"Multiparametric MRI-based radiomic nomogram for predicting HER-2 2+ status of breast cancer","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2024.111573","article-title":"Noninvasive identification of HER2-zero, -low, or -overexpressing breast cancers: Multiparametric MRI-based quantitative characterization in predicting HER2-low status of breast cancer","volume":"177","author":"Zhan","year":"2024","journal-title":"Eur J Radiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1148\/rg.220105","article-title":"Translating AI to clinical practice: overcoming data shift with explainability","volume":"43","author":"Choi","year":"2023","journal-title":"RadioGraphics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10278-023-00870-5","article-title":"Reproducibility of deep learning algorithms developed for medical imaging analysis: a systematic review","volume":"36","author":"Moassefi","year":"2023","journal-title":"J Digital Imaging"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.105111","article-title":"Transparency of deep neural networks for medical image analysis: a review of interpretability methods","volume":"140","author":"Salahuddin","year":"2022","journal-title":"Comput Biol Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.23.30603","article-title":"Development and validation of MRI radiomics models to differentiate HER2-zero, -low, and -positive breast cancer","volume":"222","author":"Peng","year":"2024","journal-title":"Am J Roentgenology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","article-title":"Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-020-01058-3","article-title":"Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study","volume":"27","author":"Li","year":"2020","journal-title":"Breast Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/bcr3114","article-title":"Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study","volume":"14","author":"Bidard","year":"2012"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5529106","article-title":"Association of preoperative serum levels of CEA and CA15-3 with molecular subtypes of breast cancer","volume":"2021","author":"Zhao","year":"2021","journal-title":"Dis Markers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19246","article-title":"Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes","volume":"8","author":"Fang","year":"2017","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.24519","article-title":"Correlations between apparent diffusion coefficient values of invasive ductal carcinoma and pathologic factors on diffusion\u2010weighted MRI at 3.0 Tesla","volume":"41","author":"Park","year":"2015","journal-title":"J Magn Reson Imaging"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2015.12.011","article-title":"Perfusion parameters in dynamic contrast-enhanced MRI and apparent diffusion coefficient value in diffusion-weighted MRI","volume":"23","author":"Lee","year":"2016","journal-title":"Acad Radiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-10198-x","article-title":"Discrimination between human epidermal growth factor receptor 2 (HER2)-low-expressing and HER2-overexpressing breast cancers: a comparative study of four MRI diffusion models","volume":"34","author":"Mao","year":"2023","journal-title":"Eur Radiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2018.09.003","article-title":"The role of diffusion weighted imaging as supplement to dynamic contrast enhanced breast MRI: Can it help predict Malignancy, histologic grade and recurrence","volume":"26","author":"Roknsharifi","year":"2019","journal-title":"Acad Radiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-012-2425-2","article-title":"Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes","volume":"22","author":"Youk","year":"2012","journal-title":"Eur Radiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2010.07.008","article-title":"Diffusion-weighted imaging in breast cancer: relationship between apparent diffusion coefficient and tumour aggressiveness","volume":"65","author":"Costantini","year":"2010","journal-title":"Clin Radiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32835ff362","article-title":"Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges","volume":"25","author":"Alameddine","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.acra.2024.07.048","article-title":"A comprehensive model outperformed the single radiomics model in noninvasively predicting the HER2 status in patients with breast cancer","volume":"32","author":"Liu","year":"2025","journal-title":"Acad Radiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10641-7","article-title":"Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics","volume":"34","author":"Zheng","year":"2024","journal-title":"Eur Radiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222646","article-title":"Multiparametric MRI and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers","volume":"308","author":"Ramtohul","year":"2023","journal-title":"Radiology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.29447","article-title":"Preoperative differentiation of HER2\u2010Zero and HER2\u2010Low from HER2\u2010Positive invasive ductal breast cancers using BI\u2010RADS MRI features and machine learning modeling","volume":"61","author":"Zhou","year":"2025","journal-title":"J Magn Reson Imaging"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1148\/ryai.2021210097","article-title":"Toward generalizability in the deployment of artificial intelligence in radiology: role of computation stress testing to overcome underspecification","volume":"3","author":"Eche","year":"2021","journal-title":"Radiology: Artif Intell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.compmedimag.2024.102443","article-title":"MRI-based vector radiomics for predicting breast cancer HER2 status and its changes after neoadjuvant therapy","volume":"118","author":"Zhang","year":"2024","journal-title":"Comput Med Imaging Graphics"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1824808\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:38:38Z","timestamp":1781757518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1824808\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":39,"alternative-id":["10.3389\/fonc.2026.1824808"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1824808","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1824808"}}